Kevin Schaffer, MD
Allergy & Immunology · Snellville, GANPI 1104872084
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.4%), consulting fees and education — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Covis Pharma GmbH at 44.6% of the total. Reporting peaked in 2019 at $6,547 and has fallen 96.2% since, to $249 in 2024.
Across 279 payments — averaging $44.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Covis Pharma GmbH$6K
- Biocryst US Sales Co., LLC$1K
- AstraZeneca$1K
- GSK$528
- Sanofi$433
- Pfizer$424
- plus $3K from 20 others
What the payments were for
- Consulting fees$5,91247%
- Food & beverage$6,55852%
- Education$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Covis Pharma GmbH | 16 | $5,572 |
| Biocryst US Sales Co., LLC | 18 | $1,260 |
| AstraZeneca | 55 | $1,194 |
| GSK | 30 | $528 |
| Sanofi | 8 | $433 |
| Pfizer | 28 | $424 |
| Pharming Healthcare, Inc. | 16 | $374 |
| Octapharma USA, Inc. | 6 | $365 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $363 |
| CSL Behring | 12 | $326 |
| Kaleo, Inc. | 15 | $273 |
| Grifols USA, LLC | 13 | $267 |
| Sanofi-aventis U.S. LLC | 3 | $226 |
| Optinose US, Inc. | 7 | $145 |
| Amgen | 6 | $132 |
| Novartis | 6 | $129 |
| Regeneron Healthcare Solutions, Inc. | 5 | $113 |
| Boehringer Ingelheim | 3 | $74 |
| Shire North American Group Inc | 4 | $69 |
| Teva Pharmaceuticals USA, Inc. | 4 | $63 |
| Blueprint Medicines Corporation | 2 | $47 |
| Merck | 2 | $37 |
| AbbVie | 2 | $34 |
| LEO Pharma Inc. | 1 | $21 |
| Biocryst Pharmaceuticals, Inc. | 1 | $19 |
| Alk-abello, Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,506 in reported general payments places this provider in the 75th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $55,967 |
| TezspireTezepelumab-Ekko | 11 | $48,460 |
| Dupixent SyringeDupilumab | 12 | $44,904 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $17,265 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $11,772 |
| DuleraMometasone/Formoterol | 21 | $9,162 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $8,856 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,583 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,413 |
| AlvescoCiclesonide | 15 | $4,388 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $3,906 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $3,201 |
| Epinephrine | 26 | $2,981 |
| Ipratropium Bromide | 68 | $2,382 |
| Azelastine Hcl | 38 | $2,135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $528 | $73,23286 claims |
| AstraZenecaTezspire, Symbicort | $1,194 | $60,23240 claims |
| MerckDulera | $37 | $9,16221 claims |
| Boehringer IngelheimCombivent Respimat | $74 | $5,58311 claims |
| Covis Pharma GmbHAlvesco | $5,572 | $4,38815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Snellville
- Michael BlaissRoswell$1.1M
- Deborah BirxAtlanta$470K
- Tracy BridgesAlbany$364K
- Jack EadesMacon$237K
- Stanley FinemanMarietta$186K
- Robert CartwrightColumbus$169K
- Robert ChrzanowskiColumbus$115K
- Belinda GrahamSmyrna$94K
- Lily HwangRoswell$88K
- Paul RabinowitzAtlanta$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.